BRTX

Business Context and Reporting Period

Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: BRT develops therapeutic products using adult stem cells. Key programs include brtxDISC (BRTX-100 for lumbar disc disorders), the ThermoStem Program (brown adipose for metabolic disorders), and a biologics-based cosmetic products business. The company operates as a non-accelerated filer and smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased significantly to $233,600 in Q3 2024 from $30,700 in Q3 2023. This was driven by $230,700 in new cosmetic product sales (exclusive supply agreement with Cartessa Aesthetics), offset by a decline in royalty revenue from disc procedures.
• Operating Expenses: Total operating expenses decreased to $2.5 million in Q3 2024 from $3.1 million in Q3 2023. General and Administrative (G&A) expenses dropped 49% primarily due to a $1.2 million reduction in stock-based compensation. Research and Development (R&D) expenses increased 63% due to higher lab supply costs and clinical trial recruitment.
• Net Income/Loss Volatility: The company reported a net loss of $1.1 million in Q3 2024, compared to a net income of $4.8 million in Q3 2023. The prior year income was largely driven by a $7.7 million gain on the change in fair value of warrant liabilities, whereas the current quarter saw a $1.0 million gain in the same category.
• Financing Activity: During the nine months ended September 30, 2024, the company raised approximately $7.5 million in net proceeds through a warrant exercise and issuance program.

Outlook, Risks, and Management Commentary

• Liquidity: Management believes current cash and investments ($13.1 million total) are sufficient to fund operations for at least 12 months. However, the company expects to continue incurring net losses and will require additional financing to complete clinical trials and attain profitability.
• Subsequent Event: On November 6, 2024, the company entered into an at-the-market offering agreement to sell up to $3.6 million of common stock.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024. Material weaknesses persist regarding adherence to formal policies, risk assessment, and accounting for warrant liabilities. Remediation efforts are underway with external consultants.
• Risk Factors: Significant risks include the ability to obtain necessary financing, FDA enforcement actions regarding the cosmetic product manufactured for Cartessa (potential reclassification as a therapeutic), and the success of clinical trials for BRTX-100.
• Unusual Items: The financial statements include a restatement of prior periods. A significant non-cash gain of $1.7 million was recorded in the nine months ended Sept 30, 2024, related to the exchange of existing warrants for new warrants and common stock.

Investor Verification Checklist

• Restatement Impact: Verify the full extent of the restatement of previously issued financial statements referenced in the 10-K/A and its impact on historical comparability.
• Warrant Liability Volatility: Monitor the fair value of warrant liabilities ($3.5 million), as changes in stock price significantly impact reported net income/loss.
• Cash Burn Rate: Assess the sustainability of the current cash position given the $5.9 million cash used in operating activities over the last nine months.
• Regulatory Status: Confirm the FDA's stance on the cosmetic product supply agreement with Cartessa to ensure no enforcement actions threaten this revenue stream.
• Internal Control Remediation: Review progress on remediation of material weaknesses in internal controls over financial reporting.